Molecular Therapy: Oncolytics (Sep 2022)

Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence

  • Andrew B. Satterlee,
  • Denise E. Dunn,
  • Alain Valdivia,
  • Daniel Malawsky,
  • Andrew Buckley,
  • Timothy Gershon,
  • Scott Floyd,
  • Shawn Hingtgen

Journal volume & issue
Vol. 26
pp. 49 – 62

Abstract

Read online

Genetically engineered neural stem cells (NSCs) are a promising therapy for the highly aggressive brain cancer glioblastoma (GBM); however, treatment durability remains a major challenge. We sought to define the events that contribute to dynamic adaptation of GBM during treatment with human skin-derived induced NSCs releasing the pro-apoptotic agent TRAIL (iNSC-TRAIL) and develop strategies that convert initial tumor kill into sustained GBM suppression. In vivo and ex vivo analysis before, during, and after treatment revealed significant shifts in tumor transcriptome and spatial distribution as the tumors adapted to treatment. To address this, we designed iNSC delivery strategies that increased spatiotemporal TRAIL coverage and significantly decreased GBM volume throughout the brain, reducing tumor burden 100-fold as quantified in live ex vivo brain slices. The varying impact of different strategies on treatment durability and median survival of both solid and invasive tumors provides important guidance for optimizing iNSC therapy.

Keywords